Hugh Kearney1, Tucker Price2, Jane Cryan2, Alan Beausang2, Seamus Looby3, Francesca M Brett2, Michael Farrell2. 1. Department of Neuropathology, Beaumont Hospital, Beaumont Road, Dublin, Ireland. hughkearney@yahoo.com. 2. Department of Neuropathology, Beaumont Hospital, Beaumont Road, Dublin, Ireland. 3. Department of Neuroradiology, Beaumont Hospital, Dublin, Ireland.
Abstract
BACKGROUND: Knowledge of the clinical outcome in tumefactive demyelination remains limited. AIMS: This study aims to characterise the natural history of biopsy-proven, pathogen-free, cerebral demyelination in an adult Irish population. METHODS: We identified all patients with biopsy-proven demyelination in a single neuropathology centre between 1999 and 2017. A baseline, and at least one follow-up MRI scan was available in each instance (mean of 3 scans per patient), together with both the presenting and most recent clinical details including disability level and disease-modifying drugs. RESULTS: In 21 patients, white matter biopsies showed the following: macrophages with myelin debris, myelin-axonal dissociation, reactive astrocytes and occasional lymphocytes. During a mean follow-up time of 8 years (± 4.4), 17 patients developed MS, confirmed both clinically and on MRI, using the 2010 McDonald criteria: 11 relapsing remitting (RR) MS, four secondary progressive and two primary progressive MS. Four patients had a monophasic illness with lesion regression, without clinical or radiological evidence of any further disease activity on follow-up. The patients with progressive MS had significantly higher levels of physical disability than either the RRMS or monophasic patients. CONCLUSION: Uniform white matter subacute demyelination is associated with a diverse clinical course ranging from a monophasic illness to progressive MS, suggesting that extraneous factors distinct from the basic pathology significantly influence the clinical course in MS.
BACKGROUND: Knowledge of the clinical outcome in tumefactive demyelination remains limited. AIMS: This study aims to characterise the natural history of biopsy-proven, pathogen-free, cerebral demyelination in an adult Irish population. METHODS: We identified all patients with biopsy-proven demyelination in a single neuropathology centre between 1999 and 2017. A baseline, and at least one follow-up MRI scan was available in each instance (mean of 3 scans per patient), together with both the presenting and most recent clinical details including disability level and disease-modifying drugs. RESULTS: In 21 patients, white matter biopsies showed the following: macrophages with myelin debris, myelin-axonal dissociation, reactive astrocytes and occasional lymphocytes. During a mean follow-up time of 8 years (± 4.4), 17 patients developed MS, confirmed both clinically and on MRI, using the 2010 McDonald criteria: 11 relapsing remitting (RR) MS, four secondary progressive and two primary progressive MS. Four patients had a monophasic illness with lesion regression, without clinical or radiological evidence of any further disease activity on follow-up. The patients with progressive MS had significantly higher levels of physical disability than either the RRMS or monophasic patients. CONCLUSION: Uniform white matter subacute demyelination is associated with a diverse clinical course ranging from a monophasic illness to progressive MS, suggesting that extraneous factors distinct from the basic pathology significantly influence the clinical course in MS.
Authors: S J Pittock; R L McClelland; S J Achenbach; F Konig; A Bitsch; W Brück; H Lassmann; J E Parisi; B W Scheithauer; M Rodriguez; B G Weinshenker; C F Lucchinetti Journal: J Neurol Neurosurg Psychiatry Date: 2005-12 Impact factor: 10.154
Authors: Marco Rovaris; Elda Judica; Jaume Sastre-Garriga; Alex Rovira; Maria Pia Sormani; Beatrice Benedetti; Tijmen Korteweg; Nicola De Stefano; Zhaleh Khaleeli; Xavier Montalban; Frederik Barkhof; David H Miller; Chris Polman; Alan J Thompson; Massimo Filippi Journal: Mult Scler Date: 2008-01-21 Impact factor: 6.312
Authors: L K Fisniku; P A Brex; D R Altmann; K A Miszkiel; C E Benton; R Lanyon; A J Thompson; D H Miller Journal: Brain Date: 2008-01-29 Impact factor: 13.501